Introduction
============

Multiple sclerosis (MS) is a debilitating disease of the central nervous system (CNS) affecting the quality of life in mainly young people. Inflammatory demyelination, axonal degeneration and gliosis constitute major pathological hallmarks of MS. Although there are a variety of pharmaceutical drugs available to prevent relapses and slow down progression in MS, lack of proper understanding of its pathogenesis poses a great challenge for a complete cure of disease. During the relapsing-remitting MS subtype (RRMS), the patient's brain itself is capable of repairing the damage, remyelinating the axon and recovering the neurological function. Furthermore, CSF is in close proximity with brain parenchyma and contains proteins and other factors, which may influence the cellular physiology of brain cells. Indeed, CSF is a promising biofluid in the search for biomarkers and disease associated proteins in MS, both with respect to inflammatory and neurodegenerative processes. Studies revealed that exposure of human CSF in xenogeneic models cause neurotoxicity in culture, although the molecular mechanisms remained poorly understood ([@B83]; [@B2]). Our group found that ceramides present in CSF derived from MS patients impair neuronal bioenergetics in rat neuronal cultures ([@B75]). Increased energy requirement following Na+/K+ ATPase redistribution in demyelinated axons ([@B78]) and disturbed metabolic or trophic support due to damaged oligodendrocytes ([@B43]) is imputable to axonal injury which causes irreversible permanent neurological deficits in MS patients.

Several lines of evidence have indicated that metabolic disturbances contribute to the pathogenesis of neurodegenerative diseases including Alzheimer's and Huntington's disease ([@B52]; [@B63]; [@B68]; [@B5]; [@B10]; [@B44]) or MS ([@B35]; [@B66]; [@B47]; [@B34]; [@B9]; [@B61]; [@B49]). Furthermore, a number of gene expression studies have been conducted in peripheral mononuclear white blood cells ([@B17]; [@B77]; [@B6]; [@B38]; [@B32]), in MS brain tissues ([@B4]; [@B79]; [@B13]) and in CSF ([@B12]). In amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder, mitochondrial deformities have been reported by several studies ([@B1]; [@B3]; [@B62]; [@B65]). Furthermore, several investigations have revealed changes in the mitochondrial electron transport chain of ALS patients. These include decreased complex I activity and cytochrome c oxidase activity in skeletal muscle, spinal cords and motor cortex of ALS patients ([@B8]; [@B23]; [@B80]; [@B7]). ALS patients who are in their benign stage showed an elevated oxidative phosphorylation capacity of skeletal muscle mitochondria whereas patients in their progressive stage showed a significantly reduced activity of muscular mitochondrial respiratory complex IV ([@B20]). These studies suggest perturbation in mitochondrial-associated pathways and eventually a variation in energy generation process. [@B25] have shown that the rate of glucose uptake, oxygen consumption, and lactate formation is increased significantly in skeletal muscles of ALS patients indicating disturbance in glucose metabolic pathways. Moreover, the levels of glucose within the CNS are significantly decreased in ALS patients ([@B15]). Apart from identifying defects in glucose metabolism in ALS, [@B18] found abnormalities in glycogen metabolism in spinal cords of ALS patients. All of these case studies reveal significant variations in carbohydrate metabolism in ALS, which may be related to the underlying pathology of ALS.

In support of human studies, animal mouse models of ALS have also displayed metabolic dysfunctions. In particular, mutant SOD1 mice model contains a modified structure of mitochondria, as observed in motor neurons ([@B14]; [@B82]; [@B62]; [@B41]). Furthermore, the activity of complex I of electron transport chain is significantly reduced in SOD1G93A mice suggesting mitochondrial abnormality ([@B36]; [@B51]). Other investigations have also revealed impaired electron transport chain and defects in ATP synthesis in spinal cords of mutant SOD1 mice ([@B51]). It was found that glucose levels and ATP generation declined to a great extent within CNS tissues in SOD1G93A mice ([@B11]). Other neurodegenerative disorders, such as Alzheimer's disease, have also shown aberrations in mitochondrial DNA and in associated enzymes ([@B87]). In this study, mitochondrial DNA and cytochrome oxidase-1 levels are elevated in hippocampal neurons, compared to control brains, even though the number of mitochondria per neuron is declined. Altogether, evidence from these studies indicates that glucose metabolism, oxidative balance, and ATP production are extensively impaired in ALS and other neurodegenerative diseases.

Findings from our previous work demonstrated that *Gapdh*, a commonly used reference gene, showed downregulated expression when cerebellar granule neurons were treated with CSF obtained from distinct clinical types of MS and NMO patients ([@B50]). *Gapdh* is a key glycolytic enzyme involved mainly in the production of ATP. Standard reference genes such as *Gapdh* and b*-actin* have been demonstrated to show variable expression in different experimental conditions ([@B85]; [@B72]; [@B71]; [@B27]; [@B56]). We therefore, investigated the expression stability of six reference genes in OPCs treated with CSF from MS and NMO patients, using *geNorm* and *NormFinde*r algorithms. Same reference genes that we studied previously in neuronal analysis ([@B50]) were selected. *geNorm* program defines the gene stability as the average pairwise variation of a particular gene with all other reference genes and ranks the genes according to their average expression stability (*M*). The gene with minimum *M*-value is considered to be highly stable whereas the gene with highest *M*-value is least stable. The *geNorm* algorithm is based on the assumption that the reference genes selected for analysis are not co-regulated. Keeping this in mind, we selected genes that were regulated differently in order to elude unbiased results. Another program, *NormFinder*, ranks the candidate reference genes based on the combined estimates of both intra- and intergroup variations. In general, more than one reference genes are recommended to use for the correct normalization of gene expression data ([@B85]; [@B29]; [@B73]; [@B74]; [@B58]).

The goal of the present study was to investigate the effect of CSF on OPCs, which could contain factors that damage OPCs during attempts at brain repair. Additionally, we wanted to assess the expression stability of various commonly used reference genes when rat OPCs were treated with CSF from MS and NMO patients. This step would enable us to accurately normalize target mRNA transcripts in gene expression experiments.

Materials and Methods {#s1}
=====================

Study Approval
--------------

All procedures were approved by the Committee of Animal Care of Prince Felipe Research Center (CIPF, Valencia,) in accordance with the regulations of the European Union and Spanish legislations, within the expedient PS09/00976 of the Institute of Health Carlos III. Written informed consent was obtained from all the patients and authorized by the Ethical Committee of the Hospital Universitario y Politecnico La Fe and Hospital Clínico Universitario de Valencia for this research ([@B50]).

Patient Cohort
--------------

A total of 59 patients were recruited and CSF samples were obtained from the Department of Neurology, Hospital Universitario y Politécnico La Fe and Hospital Clínico Universitario de Valencia. Out of 59 patients, 21 had inflammatory MS (11 G+/M+ and 10 G+/M-), 8 had medullary subtype (Med), 11 had primary progressive MS (PPMS), 9 had NMO, and 10 were non-inflammatory neurological controls (NIND patients) (**Table [1](#T1){ref-type="table"}**). In CSF, apart from factors related to MS or NMO, there are factors from other diseases that produce their action. This must be considered as "*background noise*" as average population. Mixing of total CSF samples in all clinical forms may potentiate the factors related to MS. Therefore, samples from patients suffering from the same form of MS (e.g., G+/M-, G+/M+, medullary, PPMS or controls) were pooled together, then several OPCs cultures were treated with the CSF mix, and the RNA were extracted from the culture (see below).

###### 

Clinical characteristics of the patients.

  --
  --

Multiple sclerosis patients were defined and grouped in different clinical courses, according to the current criteria ([@B46]) and diagnosed according to McDonald criteria. They all met the following characteristics: oligoclonal IgG bands (OCGB) present, not in a phase of relapse, and have spent more than a month after the last dose of steroids. [@B81] criteria were used to diagnose patients with NMO disease. Patients suffered relapses of optic neuritis and myelitis, and two of the three criteria, normal MRI or that did not accomplish the Patty criteria for MRI diagnosis of MS.

Patient Characteristics
-----------------------

Inflammatory MS (RRMS and SPMS forms): MS is categorized into: (1) Relapsing remitting MS (RRMS) that later develops into secondary progressive stage (SPMS); and (2) primary progressive MS (PPMS). Over 95% of patients with MS show oligoclonal bands (OCBs) of IgG in CSF (G+) ([@B42]) and 40% show IgM OCBs in CSF (M+) related to a more aggressive course of disease ([@B64]). In this study we also classified and named inflammatory MS into "*G*+*/M*-" and "*G*+*/M*+" subtypes (see below) on the basis of aggressivity and prognosis that is more complete than just RRMS or PPMS. In addition, we have studied separately a set of patients with MS but with a predominant affectation of the spinal cord, because these patients have some peculiarities, and we wanted to explore if they have some differences in light of our experiments. The most aggressive cases termed as "*medullary*" have more spinal injuries.

Relapsing-remitting multiple sclerosis (RRMS) IgG+/IgM- clinical form of MS: Patients named as "*G*+*/M-subtype*" had IgG antibodies (+) but no IgM (-) oligoclonal antibodies detected in the CSF of brain. RRMS IgG+/IgM+ clinical form of MS: Patients named as "*G*+*/M*+ *subtype*" had both IgG antibodies (+) and IgM (+) oligoclonal antibodies detected in the CSF of brain. Medullary (Med) clinical form of MS: All these patients were positive for OCGBs and negative (most frequent) or not for oligoclonal IgM bands (OCMBs) in CSF as well as presence of diffuse hyperintensity signal in the spinal cord and with mainly relapses from this location. The patients accomplished also Swanton's criteria for dissemination in time. Primary progressive MS (PPMS): These patients are characterized by progressive decline in neurological disability. Neuromyelitis optica (NMO) patients: Individuals that met at least two of the following three features. (1) Long extensive transverse myelitis (\>3 vestibule bodies); (2) Antibodies against aquaporin-4; (3) Normal brain at the first event Controls \[Non-Inflammatory Neurological Diseases (NIND)\]: Individuals who were suspected to have MS but after protocolized analysis were not diagnosed with MS.

Cerebrospinal Fluid Samples of Patients
---------------------------------------

Cerebrospinal fluid samples were obtained by lumbar puncture at the time of diagnosis. No patient had received treatment with immunosuppressive drugs, immunomodulators or corticosteroids for at least 1 month prior to the extraction of CSF. The routine clinical extraction of CSF from patients was 10 mL obtained by lumbar puncture in subarachnoid space under sterile conditions every 3--6 months. The samples were centrifuged for 10 min at 700 × *g* and aliquots were frozen and stored at -80°C in 1 ml aliquots until use. To preserve the integrity of the samples, the aliquots were used just once in an experiment without re-frozen.

Primary Cultures of OPCs from the Neonatal Rat Brain
----------------------------------------------------

The OPCs were isolated from the cortex of postnatal day 1 Wistar rats (Harlan Iberica) and grown for 1 week as mixed glial cultures according to a modified McCarthy and deVellis procedure ([@B54]). Differential shaking, followed by magnetic beads immunoselection, was used to isolate progenitors ([@B28]). Briefly, cells were incubated with the A2B5 antibody, purified using magnetic beads (Miltenyi Biotec), and then plated at a density of 2 × 10^5^ cells/ml on poly-[D]{.smallcaps}-lysine coated 10 cm plates. OPC cells were allowed to proliferate for 48 h in chemically defined media (ODM) supplemented with growth factors (GFs) \[20 ng/mL basic fibroblast growth factor (bFGF) and 10 ng/mL platelet-derived growth factor AA (PDGF-AA)\] prior to treatments indicated below. This procedure led to a 95% pure population of A2B5+ cells that expressed *Myelin* and *GalC*.

CSF Treatment and RNA Extraction
--------------------------------

Treatment of OPC was conducted by culturing the cells in a 1:1 dilution of CSF and chemically defined medium supplemented with growth factors to allow a total concentration of 20 ng/ml bFGF and 10 ng/ml PDGF-AA. In these conditions OPC remain proliferative and this does not interfere with their survival or differentiation. We performed an MTT cellular toxicity assay to determine whether CSF-exposed OPCs were viable, and no difference was detected amongst the CSF groups tested (*p* \> 0.05) ([@B28]).

The RNA was extracted from OPCs treated cells using the Qiagen RNeasy RNA extraction kit according to the manufacturer's instructions. The RNA concentration was determined spectrophotometrically at 260 nm using the Nanodrop 1000 spectrophotometer (V3.7 software) and the quality of every RNA sample was measured by means of the absorbance ratio at 260/280 nm and by capillary electrophoresis using 2100 Bioanalyzer instrument (Agilent). For microarray assays (see below), we used samples with OD (*A*~260~/*A*~280~) ratio value \> 1.8 and an OD (*A*~260~/*A*~230~) ratio \> 1.9 and a minimum RNA Integrity Number (RIN) score of 9.8 (mainly 10) in the Total RNA Nano Series.

Selection of Reference Genes
----------------------------

We selected a panel of reference genes from microarray data that we used in neuronal analysis ([@B50]), to normalize expression of target mRNA transcripts. From the microarray data we determined the changes of gene expression in the different MS and NMO patients, and evaluated their expression stability using *geNorm* and *NormFinde*r algorithms. Candidate reference genes, included β-actin (*ActB*), hypoxanthine guanine phosphoribosyl-transferase (*Hprt*), mitochondrial ribosomal protein L19 (*Mrpl19*), transferrin receptor (*Tfrc*), microglobulin β2 (*B2m*), and glyceraldehyde-3-phosphate-dehydrogenase (*Gapdh*), were selected for evaluation. The function and references of the genes are listed in **Table [2](#T2){ref-type="table"}**. Primer sequences and amplification summary are listed in **Table [3](#T3){ref-type="table"}**.

###### 

Panel of six candidate housekeeping genes selected for expression analysis.

  Gene symbol   Gene name                                         mRNA accession number   Function                                                  Reference
  ------------- ------------------------------------------------- ----------------------- --------------------------------------------------------- --------------------------------
  *ActB*        β-Actin                                           NM_031144               Cytoskeletal structural Protein                           [@B69]
  *Hprt*        Hypoxanthine guanine phosphoribosyl transferase   NM_012583               Metabolic salvage of purines                              [@B21]
  *Mrpl19*      Ribosomal protein L19                             NM_031103               Unclear                                                   [@B86]
  *Tfrc*        Transferrin receptor                              NM_022712               Iron delivery from transferrin to cells                   [@B26]
  *B2m*         Microglobulin-β-2                                 NM_012512               Major histocompatibility complex class I                  [@B84]
  *Gapdh*       Glyceraldehyde-3-phosphate-dehydrogenase          NM_017008               NAD+ dependent glyceraldehyde-3-phosphate dehydrogenase   [@B26]; [@B22]; [@B30]; [@B55]

###### 

Primer sequences and amplification summary.

  -----------------------------------------------------
  Gene      Primer Sequence (5′→3′)      Product size
  --------- ---------------------------- --------------
  *Actb*    F: ATTGAACACGGCATTGTCAC\     294
            R: ACCCTCATAGATGGGCACAG      

  *Hprt*    F: CCTCTCGAAGTGTTGGATACAG\   105
            R: TCAAATCCCTGAAGTGCTCAT     

  *Rpl19*   F: ACCTGGATGCGAAGGATGAG\     139
            R: CCATGAGAATCCGCTTGTTT      

  *Ldha*    F: AGGAGCAGTGGAAGGATGTG\     214
            R: AGGATACATGGGACGCTGAG      

  *Tfrc*    F: GTTGTTGAGGCAGACCTTCA\     112
            R: ATGACTGAGATGGCGGAAAC      

  *B2m*     F: GTCGTGCTTGCCATTCAGA\      116
            R: ATTTGAGGTGGGTGGAACTG      

  *Gapdh*   F: GGAAACCCATCACCATCTTC\     200
            R: GTGGTTCACACCCATCACAA      
  -----------------------------------------------------

F, forward primer; R, reverse primer. Annealing temperature was 60° in whole amplicons.

Determination of Reference Gene Expression Stability
----------------------------------------------------

To determine the stability of these genes, we employed publicly available software tools named *geNorm* and *NormFinder*. A statistical test was applied to look for significant differences between experimental conditions for each candidate reference gene. A one-way analysis of variance (ANOVA) was conducted to determine the significantly variable genes. A *p*-value \< 0.05 was considered statistically significant.

Gene Microarray, Data Normalization and Gene Validation
-------------------------------------------------------

Isolated RNA from OPC treated cells were subjected to one color microarray-based gene expression analysis (Agilent Technologies). The labeled cRNA was hybridized to the Agilent SurePrint G3 Rat GE 8x60K Microarray (GEO-GPL13521, *in situ* oligonucleotide), according to the manufacturer's protocol. We used four microarrays per MS type of patients. Briefly, the mRNA was reverse transcribed in the presence of T7-oligo-dT primer to produce cDNA. cDNA was then *in vitro* transcribed with T7 RNA polymerase in the presence of Cy3-CTP to produce labeled cRNA. The labeled cRNA was hybridized to the Agilent Sure Print G3 Rat GE 8x60K Microarray according to the manufacturer's protocol. The arrays were washed, and scanned on an Agilent G2565CA microarray scanner at 100% PMT and 3 μm resolution. The intensity data was extracted using the *Feature Extraction Software* (Agilent). 75th percentile signal value was used to normalize Agilent one-color microarray signals for inter-array comparisons. After normalization, the data was filtered in order to exclude probesets with low expression and/or affected by differences between the laboratories.

Differentially expressed genes were identified by comparing average expression levels in MS and NMO cases and controls. mRNA expression (in terms of absolute fold change) in OPCs treated with CSF of MS and NMO individual patients was compared with gene expression in OPC exposed to CSF from neurological control patients. Fold change cut off was considered as 2. The microarrays data correspond to at least 3--4 independent assay per group of individual MS or NMO patients and controls.

Statistical Analysis
--------------------

Statistical analysis was conducted after background noise correction using *NormExp* method. Differential expression analysis was carried out on non-control probes with an empirical Bayes approach on linear models ([@B67]). Results were corrected for multiple testing hypothesis using false discovery rate (FDR), and all statistical analyses were performed with the *Bioconductor project*^[1](#fn01){ref-type="fn"}^ in the *R statistical environment*^[2](#fn02){ref-type="fn"}^. To filter out low expressed features, the 30% quartile of the whole array was calculated, and probe sets falling below threshold were filtered out. After merging the probes corresponding to the same gene on the microarray, the statistical significance of difference in gene expression were assessed using a standard one-way ANOVA followed by Tukey's HSD *post hoc* analysis (cut-off *p* \< 0.01 and FDR \<0.1). All data processing and analysis including PCA plot was carried out using R functions.

Analysis of Gene--Gene Interaction Networks Using String v10 Software
---------------------------------------------------------------------

We used STRING v10 software and correlated the gene interaction in different disease subtypes in OPCs ([@B70]; STRING database)^[3](#fn03){ref-type="fn"}^. We defined a parameter to "*integrate*" our data as "*Cumulative Flux Index* or *CFI*" within the network to compare our experimental MS conditions.

The values mean that the reduction of local flux due to the inhibition of an enzymatic activity in a specific gene affected synergically to the whole metabolic flux network. It means that as more genes were down regulated, the total flux was reduced as a cumulative factor that we integrated as the total CFI of the network.

Results
=======

Demographic and Clinical Profiles of MS, NMO, and NIND Groups
-------------------------------------------------------------

Baseline characteristics of the study population are described in **Table [4](#T4){ref-type="table"}**. Prevalence of MS was found more in women (75%) than in men. Mean age of MS patients was 30.7 ± 9.7 years whereas 25.6 ± 15 years for NMO patients. According to the classical clinical classification, that only takes care of the general characteristics of MS patients, and classified as RRMS, SPMS, and PPMS, there were significant differences observed in age at the beginning of PPMS and the other two MS forms (*p* \< 0.003); Expanded Disability Status Scale (EDSS) of RRMS and the two other MS forms (*p* \< 0.001); evolution time from the first to the second episode between PPMS and RRMS (*p* = 0.043) (**Table [5](#T5){ref-type="table"}**). In patients experiencing a progressive course, evolution time was similar in secondary progressive cases and in cases that were progressive from onset (13.5 vs. 13.8) (**Table [5](#T5){ref-type="table"}**).

###### 

General characteristics of series studied.

                     Controls (*n* = 10)   MS patients (*n* = 40)   NMO patients (*n* = 9)   *P*
  ------------------ --------------------- ------------------------ ------------------------ -------------------
  \% females (*n*)   60.0 (6)              75.0 (30)                55.6 (5)                 0.40 (χ^2^)
  Age (mean, *SD*)   40.3 (19.5)           30.7 (9.7)               25.6 (15.0)              0.04 (Anova test)
  EDSS               NA                    4.5 (2.3)                4.6 (2.8)                0.94 (*t*-test)
  Evolution time     NA                    11.1 (6.6)               11.8 (9.7)               0.79 (*t*-test)

###### 

Characteristics of MS patients according to clinical classification.

                     RRMS (*n* = 18)   SPMS (*n* = 11)   PPMS (*n* = 11)   *P*
  ------------------ ----------------- ----------------- ----------------- ----------------------
  \% females (*n*)   83.3 (15)         72.7 (8)          63.6 (7)          0.48 (χ^2^)
  Age (mean, *SD*)   27.3 (7.2)        27.9 (7.3)        38.9 (11.2)       0.003 (Anova test)
  EDSS               2.4 (1.2)         6.2 (1.5)         6.3 (1.1)         \<0.001 (Anova test)
  Evolution time     8.1 (5.4)         13.5 (7.8)        13.8 (5.7)        0.043 (Anova test)

In the **Table [6](#T6){ref-type="table"}** we organize the MS patients paying attention to data we obtained in which the presence of CSF-restricted IgM OCB was associated with an active inflammatory disease phenotype in PPMS patients with more active inflammatory disease ([@B76]). With this working classification, we found significant differences in the age at beginning between PPMS and the other two MS forms (RRMS and SPMS) (*p* \< 0.003) (**Table [6](#T6){ref-type="table"}**). People with PPMS are usually older at the time of diagnosis, with an average age of 40. Furthermore, different subtypes of MS help to predict disease severity and response to treatment hence their categorization is important. Moreover, we found significant differences in EDSS between RRMS and the two other MS forms (SPMS and PPMS) (*p* \< 0.001) (**Table [6](#T6){ref-type="table"}**). Although nerve injury always occurs, the pattern is specific for each individual with MS. Disease severity and disability increases from RRMS to SPMS course and in PPMS subtype, symptoms continually worsen from the time of diagnosis rather than having well-defined attacks and recovery. PPMS usually results in disability earlier than relapsing-remitting MS.

###### 

Characteristics of MS patients according to new proposal and working classification.

                     RRMS and SPMS   PPMS (*n* = 11)   *p*                        
  ------------------ --------------- ----------------- ------------ ------------- -------------
  \% females (*n*)   90 (9)          81.8 (9)          62.5 (5)     63.6 (7)      0.40 (χ^2^)
  Age (mean, SD)     26.7 (4.8)      26.3 (8.7)        31.4 (7.0)   38.9 (11.2)   0.005
  EDSS               2.5 (1.5)       3.4 (2.2)         6.2 (1.4)    6.3 (1.1)     \<0.001
  Evolution time     8.9 (6.3)       10.8 (5.9)        8.5 (3.1)    13.8 (5.7)    0.154

Identification of Stably Expressed Reference Genes in Treated OPCs
------------------------------------------------------------------

According to *geNorm* algorithm, *Mrpl19* and *Hprt1* were identified in the microarray analysis as the best reference genes, followed by *B2m* (average *M*-value: 0.102 for *Mrpl19* and *Hprt1* genes and 0.147 for *B2m* gene). Surprisingly, *ActB* and *Gapdh*, mostly used as standard housekeeping gene for normalization, showed the most unstable gene expression in OPCs that were exposed to the CSF of our experimental conditions. The use of *NormFinder* software with the data showed that *Tfrc* and *B2m* were identified as the best reference genes followed by *ActB* (average *M*-value: 0.033 for *Tfrc* and *B2m* genes and 0.087 for *ActB* gene). *Mrpl19 and Gapdh* showed the least stable gene expression in OPCs that were exposed to the CSF of our experimental conditions. **Table [7](#T7){ref-type="table"}** depicts candidate reference genes ranked in OPCs exposed to the CSF of RRMS and PPMS patients according to their expression stability by *geNorm* and *NormFinder* methods.

###### 

Candidate reference genes ranked in OPCs exposed to the CSF of RRMS and PPMS patients according to their expression stability by *geNorm* and *NormFinder* methods.

  *geNorm*   *NormFinder*                          
  ---------- -------------- ------- --- ---------- -------
  1          *Mrpl19*       0.102   1   *Tfrc*     0.033
  1          *Hprt1*        0.102   1   *B2m*      0.033
  2          *B2m*          0.147   2   *ActB*     0.087
  3          *Tfrc*         0.160   3   *Hprt1*    0.222
  4          *ActB*         0.192   4   *Mrpl19*   0.260
  5          *Gapdh*        0.272   5   *Gapdh*    0.426

M: Average expression stability. Lower

M-

value indicates more stable expression while the highest

M-

value indicates variable expression.

The expression of β-actin (*ActB*) gene was downregulated significantly, showing 37 and 42% gene expression in OPCs exposed to the CSF of G+/M+ and medullary MS as compared to control. The expression was downregulated by 37% in OPCs exposed to the CSF of NMO patients as compared to control (**Figure [1A](#F1){ref-type="fig"}**). A marked fluctuation in *ActB* gene expression was seen in OPCs exposed to the CSF of various experimental conditions. *geNorm* also identified *ActB* as highly variable gene in these experimental conditions. We conclude that this gene is not suitable to normalize gene transcripts in treated OPCs.

![Normalized expression of **(A)** *ActB*; **(B)** *B2m*; **(C)** *Hprt*; **(D)** *Mrpl19*; **(E)** *Tfrc*; **(F)** *Gapdh* reference genes in OPCs tested in distinct disease courses of multiple sclerosis. G+/M- and G+/M+: Inflammatory forms of relapsing remitting multiple sclerosis; Med: Medullary form; PPMS: Primary progressive multiple sclerosis; NMO: Neuromyelitis Optica; Control: Other non-inflammatory neurological diseases (NIND).](fncel-11-00209-g001){#F1}

The expression of β-2 microglobulin (*B2m*) gene was downregulated significantly showing 50, 48, and 58 % in OPCs exposed to the CSF of G+/M-, G+/M+ and medullary MS as compared to control. Similarly, significantly reduced expression with 43% in OPCs exposed to the CSF of NMO patients was observed as compared to control (**Figure [1B](#F1){ref-type="fig"}**). *geNorm* identified *B2m* as the third most stable gene hence this gene can be used for normalization purpose in treated OPCs.

The expression of hypoxanthine phosphoribosyltransferase (*Hprt1*) gene was downregulated significantly by 49, 38, and 49% in OPCs exposed to the CSF of G+/M-, G+/M+ and medullary MS as compared to control. Similarly the expression was around 52% significantly reduced in OPCs exposed to the CSF of PPMS and NMO patients as compared to control (**Figure [1C](#F1){ref-type="fig"}**). *geNorm* identified *Hprt1* as the most stable gene hence this gene can be used for normalization purpose in treated OPCs.

The expression of mitochondrial ribosomal protein L19 (*Mrpl19*) gene was downregulated significantly by 52, 46, and 48% in OPCs exposed to the CSF of G+/M-, G+/M+ and medullary MS as compared to control. Similarly the expression was 52 and 45% lower in OPCs exposed to the CSF of PPMS and NMO patients as compared to control (**Figure [1D](#F1){ref-type="fig"}**). *geNorm* identified *Mrpl19* as the most stable gene hence this gene can be used for normalization purpose in treated OPCs.

Similarly, reduced variation was observed in transferrin receptor (*Tfrc*) gene expression across all experimental conditions (**Figure [1E](#F1){ref-type="fig"}**).

The data indicates that the expression of glyceraldehyde 3-phosphate dehydrogenase (*Gapdh*) gene was downregulated by 44, 54, and 49% in OPCs treated with G+/M-, G+/M+ and medullary clinical form of MS as compared to OPCs exposed to the CSF of neurological controls. Similarly, the expression was reduced by 55 and 44% in OPCs treated with the CSF of PPMS and NMO patients as compared to OPCs exposed to the CSF of non-inflammatory neurological controls (NIND) (**Figure [1F](#F1){ref-type="fig"}**). According to *geNorm* and *NormFinder* algorithms, *Gapdh* was ranked as an unstable gene for normalizing mRNA transcripts.

We conclude from this data that *Mrpl19, Hprt, Tfrc*, and *B2m* should be used to normalize the gene transcripts in experiments related to the current one, without much differences between them, and the use of *ActB* and *Gapdh* should be avoided.

Differential Expression of Genes Involved in Glucose Metabolism in OPCs by Microarray Gene Expression Profiling
---------------------------------------------------------------------------------------------------------------

Our findings in the microarray analysis revealed that genes involved in carbohydrate metabolism were differentially expressed in our experimental conditions. **Figures [2](#F2){ref-type="fig"}--[4](#F4){ref-type="fig"}** shows expression of genes involved in glycolytic pathway; TCA cycle; and oxidative phosphorylation in OPCs treated with CSF derived from MS and NMO patients normalized to gene expression in OPCs treated with CSF derived from non-inflammatory neurological controls. We have plotted the expression of genes in our experimental conditions, normalized with respect to neurological control, calculated from the absolute fold change values from microarray data.

![Normalized expression of **(A)** *Hk*; **(B)** *Gpi*; **(C)** *Aldoc*; **(D)** *Gapdh*; **(E)** *Tpi*; **(F)** *Pgk1*; **(G)** *Pgam1*; **(H)** *Eno1*; **(I)** *Eno2*; **(J)** *Pk*; **(K)** *Pkm2* genes involved in glycolytic pathway in OPCs treated with CSF of MS and NMO patients related to gene expression in OPCs treated with CSF of non-inflammatory neurological controls. OPCs: oligodendrocyte progenitor cells; Control: Neurons treated with CSF of non-inflammatory neurological controls; G+/M- and G+/M+: types of inflammatory MS; Med: Medullary MS; PP: Primary progressive multiple sclerosis; NMO: Neuromyelitis Optica. Four microarrays were used in each MS or NMO type of patients.](fncel-11-00209-g002){#F2}

![Normalized expression of **(A)** *Pdha1*; **(B)** *Aco2*; **(C)** *Idh*; **(D)** *Ogdh*; **(E)** *Sdh*; **(F)** *Mdh2* genes involved in TCA cycle in OPCs treated with CSF of MS and NMO patients related to gene expression in OPCs treated with CSF of non-inflammatory neurological controls. OPCs: oligodendrocyte progenitor cells; Control: Neurons treated with CSF of non-inflammatory neurological controls; G+/M- and G+/M+: types of inflammatory MS; Med: Medullary MS; PP: Primary progressive multiple sclerosis; NMO: Neuromyelitis Optica. Four microarrays were used in each MS or NMO type of patients.](fncel-11-00209-g003){#F3}

![Normalized expression of **(A)** *ATP5a1*; **(B)** *ATP5b*; **(C)** *Cox*; **(D)** *MT-ND2*; **(E)** *Cyc1* genes involved in oxidative phosphorylation in OPCs treated with CSF of MS and NMO patients related to gene expression in OPCs treated with CSF of non-inflammatory neurological controls. OPCs: oligodendrocyte progenitor cells; Control: Neurons treated with CSF of non-inflammatory neurological controls; G+/M- and G+/M+: types of inflammatory MS; Med: Medullary MS; PP: Primary progressive multiple sclerosis; NMO: Neuromyelitis Optica. Four microarrays were used in each MS or NMO type of patients.](fncel-11-00209-g004){#F4}

When OPCs were exposed to CSF of G+/M- RRMS patients, the expression of several glycolytic genes including *Hk (hexokinase), Gpi (Glucose-6-phosphate isomerase), Gapdh (Glyceraldehyde 3-phosphate dehydrogenase), Tpi (Triosephosphate isomerase), Pgk1 (Phosphoglycerate kinase 1), Eno1 (Enolase 1), Eno2 (Enolase 2), Pk (Pyruvate kinase)*, and *Pkm2 (pyruvate kinase M2)* was found to be decreased (**Figures [2A,B,D--F,H--K](#F2){ref-type="fig"}**). Furthermore, genes implicated in TCA cycle including *Pdha1 (pyruvate dehydrogenase alpha 1), Aco2 (Aconitate hydratase), Idh (Isocitrate dehydrogenase)*, and *Ogdh (Oxoglutarate dehydrogenase)* were downregulated (**Figures [3A](#F3){ref-type="fig"}--[D](#F3){ref-type="fig"}**). Similarly, genes involved in oxidative phosphorylation, namely *ATP5a1 (ATP synthase subunit alpha 1), ATP5b (ATP synthase subunit alpha 5b), MT-ND2 (mitochondrial encoded NADH dehydrogenase 2)*, and *Cyc1 (cytochrome c1)*, showed decreased expression as compared to neurological controls (**Figures [4A,B,D,E](#F4){ref-type="fig"}**).

When OPCs were exposed to CSF of G+/M+ RRMS patients, it was found that most of the enzymes involved in glycolysis including *Hk, Gpi, Gapdh, Tpi, Pgk1, Eno1*, and *Pk*, (**Figures [2A,B,D--H,J](#F2){ref-type="fig"}**); the related TCA cycle enzymes including *Pdha1, Aco2, Idh, Ogdh, Sdh (Succinate dehydrogenase)*, and *Mdh2 (Malate dehydrogenase 2)* (**Figures [3A](#F3){ref-type="fig"}--[F](#F3){ref-type="fig"}**); and the mitochondrial electron chain enzymes \[*MT-ND2, Cyc1, Cox (Cytochrome c oxidase), ATP5a1* and *ATP5b*\] were strongly reduced in gene expression as compared to neurological controls (**Figures [4A](#F4){ref-type="fig"}--[E](#F4){ref-type="fig"}**).

When OPCs were exposed to CSF of medullary patients, it was found that most of the enzymes involved in glycolysis including *Hk, Gpi, Gapdh, Tpi, Pgk1, Eno1, Eno2, Pk*, and *Pkm2* (**Figures [2A,B,D--F,H--K](#F2){ref-type="fig"}**), the related TCA cycle enzymes including *Pdha1, Aco2, Idh, Ogdh, Sdh*, and *Mdh2* (**Figures [3A](#F3){ref-type="fig"}--[E](#F3){ref-type="fig"}**); and the mitochondrial electron chain enzymes (*MT-ND2, Cyc1, Cox, ATP5a1*, and *ATP5b*) were strongly reduced in gene expression as compared to neurological controls (**Figures [4A](#F4){ref-type="fig"}--[E](#F4){ref-type="fig"}**).

In case of OPCs treated with CSF from PPMS patients, we found that most of the glycolytic genes, including *Hk1, Gpi, Gapdh, Tpi, Pgk1, Eno2, Pk*, and *Pkm2*, were reduced in gene expression (**Figures [2A,B,D--F,I--K](#F2){ref-type="fig"}**). Our findings also revealed down regulation of genes implicated in TCA cycle, including *Pdh, Aco2, Idh, Ogdh*, and *Sdh* (**Figures [3A](#F3){ref-type="fig"}--[E](#F3){ref-type="fig"}**). Genes of ETC, including *ComplexI/NADH:ubiquinone oxidoreductase, Cyc1, Complex IV/COX* and *ATP synthase* (both alpha and beta subunits) showed down regulated gene expression (**Figures [4A](#F4){ref-type="fig"}--[E](#F4){ref-type="fig"}**).

When OPCs were exposed to CSF of NMO patients, it was found that most of the enzymes involved in glycolysis including *Gpi, Aldoc (Fructose 1,6-bisphosphate aldolase), Gapdh, Tpi, Pgk1, Eno1, Pgam, Eno1, Eno2, Pk*, and *Pkm2* (**Figures [2B--F,H--K](#F2){ref-type="fig"}**); the related TCA cycle enzymes including *Pdha1, Aco2, Idh, Ogdh, Sdh*, and *Mdh2* (**Figures [3A](#F3){ref-type="fig"}--[F](#F3){ref-type="fig"}**); and the mitochondrial electron chain enzymes (*MT-ND2, Cyc1, Cox, ATP5a1*, and *ATP5b*) were strongly reduced in gene expression as compared to neurological controls (**Figures [4A](#F4){ref-type="fig"}--[E](#F4){ref-type="fig"}**).

Overall, the microarray data demonstrate that the genes involved in carbohydrate metabolism were differentially expressed in OPCs treated with the CSF from MS and NMO patients as compared to OPCs exposed to the CSF of neurological controls. We conclude that CSF exposure to OPCs altered the carbohydrate metabolism and may have altered the capacity of these cells to repair axonal damage in different clinical forms of MS.

Analysis of Gene--Gene Interaction Networks Using String v10 Software
---------------------------------------------------------------------

**Figure [5](#F5){ref-type="fig"}** illustrates a general metabolic network including glycolytic pathway, TCA cycle and electron transport chain with cumulative flux indexes. Gene--gene interaction network was visualized in OPCs exposed to CSF from G+/M- MS (**Figure [6A](#F6){ref-type="fig"}**); G+/M+ MS (**Figure [6B](#F6){ref-type="fig"}**); medullary MS (**Figure [6C](#F6){ref-type="fig"}**); PPMS (**Figure [6D](#F6){ref-type="fig"}**); and NMO patients (**Figure [6E](#F6){ref-type="fig"}**) generated by STRING v10. Significantly downregulated genes were indicated by blue color, and significantly upregulated genes were indicated by red color, in the STRING figure. The variation of metabolic flux, estimated with their values of CFI, in the different treatments with CSF of MS and NMO patients were integrated. CFI values were calculated as a parameter to integrate the reduced activity of the different enzymes in a specific network (glycolysis, TCA cycle and ATP generation, or together) as the expected total flux. This parameter is a simplified linear cumulative form of the flux control coefficients in the metabolic control analysis. This value roughly compares the different fluxes that may occur in the MS patients according to the number of enzymes down-regulated (after normalizing them by housekeeping gene expression) and the enzymatic activity level of each one. **Table [8](#T8){ref-type="table"}** depicts upregulated and downregulated genes in distinct MS clinical forms and NMO and their related cumulative flux index values.

![Figure illustrating cumulative flux index in glycolysis, TCA cycle and electron transport chain in glucose metabolic pathway.](fncel-11-00209-g005){#F5}

![Visualization of gene interaction network generated by STRING v10 in OPCs exposed to CSF from **(A--C)** G+/M-- RRMS; **(D--F)** G+/M+ RRMS; **(G--I)** Medullary MS; **(J--L)** PPMS; **(M--O)** NMO. Different line colors represent the types of evidence for the association between genes involved in **(A,D,G,J,M)** glycolysis; **(B,E,H,K,N)** TCA cycle and **(C,F,I,L,O)** oxidative phosphorylation in OPCs; [Red color]{.ul} signifies upregulated expression, [blue color]{.ul} signifies down regulated expression and [gray color]{.ul} signifies genes that showed no variation in their expression in our experimental conditions. LOC689343 signifies *Pk* gene and ENSRNOG00000015290 signifies *Tpi* gene.](fncel-11-00209-g006){#F6}

###### 

Differentially expressed genes which are upregulated and downregulated in distinct MS clinical forms and NMO and their related cumulative flux index.

  Clinical form   Genes upregulated   Genes downregulated   CFI   Total CFI                                Prognosis                                                                                                    
  --------------- ------------------- --------------------- ----- ---------------------------------------- ---------------------------------- ------------------------------------ -------- -------- -------- --------- -----------------
  RRMS (G+/M-)    --                  --                    --    *Hk,Gpi, Gapdh, Pgk1, Eno, Pk*           *Pdh, Ogdh, Idh, Aco2*             *Atp5a1, Atp5b, Cyc1, Cox, MT-ND2*   0.0192   0.0602   0.0119   1.3E-04   Poor prognosis
  RRMS (G+/M+)    *Pgam*              --                    --    *Hk, Gpi, Gapdh,TpiPgk1, Eno, Pk*        *Pdh, Mdh2,Sdh, Ogdh, Idh, Aco2*   *Atp5a1, Atp5b, Cyc1, Cox, MT-ND2*   0.0047   0.0024   0.017    1.9E-07   Worst prognosis
  Med             --                  --                    --    *Hk, Gpi, Gapdh, Tpi, Pgk1, Eno, Pk*     *Pdh, Sdh, Ogdh, Idh, Aco2*        *Atp5a1, Atp5b, Cyc1, Cox, MT-ND2*   0.0019   0.0124   0.0328   7.9E-07   Worst prognosis
  PPMS            --                  --                    --    *Hk, Gpi, Gapdh, Eno2, Pk*               *Aco2*                             *Atp5a1, Cox, MT-ND2*                0.0033   0.5400   0.0728   1.3E-04   --
  NMO             --                  --                    --    *Gpi, Aldoc Gapdh, Tpi, Pgk1, Eno, Pk*   *Pdh, Mdh2, Sdhaf2, Ogdh, Aco2*    *Atp5a1, Atp5b, Cyc1, Cox, MT-ND2*   0.0013   0.0055   0.0149   1.1E-07   --

With the calculation of CFI parameters, we may say that whole carbohydrate metabolic flux and ATP synthesis decreased in OPCs when exposed to CSF derived from MS and NMO patients. Our findings suggest a significant downregulation of genes involved in carbohydrate metabolism suggesting that factors present in the CSF, in our model, perturb the metabolism of OPCs.

Discussion
==========

In the present study, we found a downregulated expression of genes involved in carbohydrate metabolism in OPCs exposed to CSF from MS and NMO patients as compared to controls. We found that total cumulative flux index associated with glycolysis, TCA cycle and ATP generation declined to a great extent in G+/M+ RRMS patients (CFI: 1.9E-07) as compared to G+/M- RRMS subtype (CFI: 1.3E-04), where lower energy level may have reduced the repair process by the OPCs. G+/M- RRMS is the less severe and less aggressive form displaying oligoclonal bands of IgG antibodies (+) but no IgM (-) oligoclonal antibodies in the CSF of brain. On the other hand, G+/M+ clinical form of RRMS displayed oligoclonal bands of both IgG antibodies (+) and IgM (+) antibodies in the CSF of brain. This form was more aggressive with worse prognosis than G+/M- RRMS. In G+/M- patients, metabolic genes showed a downregulated expression leading to a reduction in the overall metabolic flux. This caused a decrease in ATP synthesis and overall ability of OPCs to repair the damaged neuronal cells, which can be related to poor prognosis and development of pathology in these patients. Our results are consistent with previous findings, which showed a reduction in ATP synthase expression in MS lesions ([@B66]). It may be indicated that genes involved in metabolism of carbohydrates and ATP synthesis were strongly affected in G+/M+ subtype in OPCs as compared to G+/M- subtype. The energy required to repair damaged neurons degenerated in MS lesions could be much lower in G+/M- RRMS less severe clinical form as compared to more aggressive G+/M+ RRMS. To combat oxidative stress generated in neurological diseases, the cells need to produce large quantities of reducing equivalents for energy production. However, insufficient energy production severely impaired the ability to repair nerve damage. We conclude that the differential expression of metabolic genes reduced the repairing potential by OPCs which could be related to worse prognosis in patients with G+/M+ RRMS type as compared to G+/M- RRMS.

In medullary MS, our results showed a significant reduction of several metabolic genes as compared to OPCs exposed to the CSF from neurological controls. Compared with non-MS patients (controls), total cumulative flux index in medullary MS dropped to a very low value (CFI: 7.9E-07) in all three metabolic pathways, similar to what occurred in G+/M+ RRMS. The most aggressive form was classified as medullary MS with a predominant affectation of the spinal cord. All these patients were positive for oligoclonal IgG bands (OCGB) and negative for oligoclonal IgM bands (OCMB) in CSF of spinal region. The drastic reduction of metabolic genes expression in both G+/M+ RRMS and medullary MS would result in bioenergetic failure eventually causing OPCs to reduce the repair of axonal damage which is correlated with worst prognosis compared with G+/M- RRMS.

Moreover, our findings demonstrated a reduced expression of genes involved in glucose metabolism in OPCs treated with CSF from PPMS patients. Altogether, total cumulative flux index in carbohydrates and ATP production was decreased strongly in OPCs (CFI: 1.3E-04) in this subtype of patients. Relapsing remitting MS (RRMS) is the most common form of MS affecting 80--90% of the patients. On the contrary, patients with primary progressive MS (PPMS) are characterized by a steady worsening of neurological symptoms with no relapse or remission affecting 10--15% of the patients. Our findings are consistent with the fact that PPMS patients are less aggressive, slower and have progressive course and a better prognosis than RRMS subtypes G+/M+ or medullary MS.

Finally, we observed a reduced carbohydrate metabolism and ATP synthesis in OPCs exposed to CSF of NMO patients compared to non-MS (controls). In addition, we found a decrease in the cumulative flux index accumulated in all three pathways.

The results indicate that the flux indexes accumulated in OPCs exposed to CSF of NMO patients decreased significantly (CFI: 1.1E-07). It has been documented that anti-NMO IgG does not have a direct effect over OPCs, and it has high affinity for the astroglial receptors ([@B48]). Despite purified cultures of OPCs were used, the 1% presence of astrocytes could explain, although unlikely, the downregulation of metabolic genes in OPCs treated with NMO derived CSF. Another, more plausible explanation (not tested), is that some NMO patients could have presented anti-MOG, a recent antibody against myelin associated oligodendrocyte, that in cases of NMO patients caused a profound oligodendropathy non-associated to astrocyte damage ([@B33]). Because anti-MOG is present in 40% of seronegative-NMO, and in our series we had four NMO patients with no anti-NMO antibodies, we cannot rule out the possibility that some patients presented anti-MOG.

Several studies have demonstrated the unmet need of energy requirement in MS, which include mitochondrial impairment in cultured neurons ([@B37]), animal models of MS ([@B57]) and in MS samples ([@B19]). Metabolic abnormalities are implicated in the pathogenesis of neurodegenerative diseases ([@B31]; [@B53]; [@B45]; [@B19]). In MS literature indicating any association between perturbed glucose metabolism with its pathogenesis is meager. [@B60], observed an increased activity of metabolic enzymes including enolase, pyruvate kinase, lactate dehydrogenase and aldolase in the CSF of patients with disseminated sclerosis. [@B39] demonstrated that B cells and antibodies reactive with *Tpi* and *Gapdh* are produced intrathecally in CSF and lesions of MS. Both TPI and GAPDH are essential metabolic enzymes involved in ATP production. Another investigation by the same group showed that these antibodies bind with TPI and GADPH, and inhibit the glycolytic activity of GAPDH but not TPI in MS patients ([@B40]).

The main findings of this study revealed a disturbed carbohydrate metabolism in OPCs treated with the CSF derived from MS and NMO subjects. Factors present in the CSF, in our model, affected the metabolism of OPCs and clearly differentiate more benign forms from the most aggressive forms in MS. The effect of CSF was different in MS aggressivity of RRMS and PPMS clinical form (G+/M-, G+/M+, Med, PPMS). G+/M+ RRMS and medullary derived CSF treated OPCs were strongly affected by reducing carbohydrate metabolism as evidenced by down regulation of most of the genes which is suggestive of least ATP synthesis. This indicates blockage of myelin repair by OPCs and correlated with worst prognosis. OPCs treated with CSF from G+/M- RRMS patients demonstrates slightly reduced carbohydrate metabolism correlated with poor prognosis.

Finally, our *geNorm* analysis revealed *Mrpl19* and *Hprt* as the most stably expressed genes followed by *B2m*, whereas β-*actin* and *Gapdh* were least stably expressed genes when OPCs were treated with diseased CSF, as revealed by *geNorm* analysis. Our findings are consistent with previous findings in which *Gapdh* and β*-actin* have been demonstrated to show variable expression in different experimental conditions ([@B29]; [@B16]; [@B24]; [@B59]; [@B50]). The results allowed us to differentiate different clinical forms and aggressivity in MS and MS from NMO. However, it is still elusive whether these alterations in metabolic gene expression cause MS and NMO or are a consequence of the disease. These findings open new avenues of study and allow the development of therapeutic agents targeted to restore the metabolic function and hence repair and/or prevent axonal damage responsible for functional disability in the patient. A greater understanding of these impaired metabolic pathways may offer new insights into more efficacious treatments for MS and NMO.
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